CG Oncology Director Leonard Post Sells 1,000 Shares While Exercising Stock Options

Director Stock Purchase at Below-Market Valuation

Leonard Post's acquisition of 1,000 common shares on July 15, 2026, at a price of $0.60 per share represents a significant discount relative to the concurrent sale price disclosed in the filing. The purchase price of $0.60 suggests the shares were acquired through a company equity compensation program, director compensation arrangement, or other corporate initiative rather than an open market transaction. This type of below-market acquisition is typical for director compensation structures at public companies, where board members receive equity grants as part of their annual or periodic compensation packages.

The filing does not explicitly disclose the specific mechanism or program through which Post acquired these shares, but the transaction code "M" in Table I indicates a non-open market acquisition. The substantial price differential between the purchase price and the subsequent sale price raises questions about the timing of when these shares were granted versus when they became saleable or when the director chose to execute the sale. This pattern of acquiring discounted shares followed by market sales is common among insiders managing their equity positions.

Exercise of Fully Vested Director Stock Options

On the same date, Post exercised director stock options with a conversion price of $0.60 per share, resulting in the acquisition of an additional 1,000 shares of common stock. The filing notes that these options were fully vested and had an expiration date of July 8, 2028, giving the director approximately two years remaining to exercise if he had not done so on July 15. The exercise of these options did not generate any direct monetary transaction at the time of exercise, as evidenced by the $0 price of the derivative security recorded in Table II.

Following this exercise, Post beneficially owned 105,077 director stock options in aggregate form, all of which were held directly and remain fully vested. The substantial option holdings suggest that Post has accumulated significant equity compensation through his service on the CG Oncology board. The decision to exercise these options at this particular time, coinciding with the share purchases and sales, indicates active portfolio management by the director.

Coordinated Share Sale Under Pre-Planned Trading Arrangement

Post sold 1,000 shares of common stock on July 15, 2026, at a price of $71.17 per share, resulting in a sale that generated substantial proceeds relative to the acquisition costs. Importantly, the filing explicitly states that this sale was executed pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on March 5, 2026. Rule 10b5-1 plans are pre-arranged trading programs that allow company insiders to establish predetermined schedules for buying or selling securities, subject to regulatory safeguards designed to prevent trading based on material non-public information.

The pre-planned nature of this sale is significant from a regulatory and compliance perspective. By establishing this plan more than four months before the actual sale execution, Post created a legally defensible structure for the transaction that demonstrates compliance with insider trading regulations. The substantial price difference between the shares sold at $71.17 and the shares acquired at $0.60 represents a significant gain per share, though the filing does not provide context regarding the acquisition dates or holding periods for the shares sold.

Ownership Position Following All Transactions

Following the completion of all three transactions on July 15, 2026, Leonard Post held zero shares of common stock directly, meaning he sold all shares acquired or held during that trading day. This resulted in a net zero position in common stock after the three-way transaction sequence. The timing and execution of acquiring shares and immediately selling them suggests that Post may have been managing specific liquidity needs or rebalancing his overall portfolio allocation within CG Oncology equity.

In contrast to his common stock position, Post's derivative securities holdings increased substantially through the option exercise. The director's beneficial ownership of 105,077 director stock options, all held directly and fully vested, represents a significant ongoing equity stake in the company. These options provide Post with future economic exposure to CG Oncology's share price performance and suggest continued confidence in the company's long-term prospects, even as he chose to liquidate his immediately available common shares.

Transaction Code and Regulatory Compliance Documentation

The Form 4 filing employs specific transaction codes to categorize each type of equity activity. The "M" code used for the stock purchase indicates a non-open market acquisition, while the "S" code for the stock sale indicates a sale on an exchange or in the open market. The "M" code used for the option exercise indicates the acquisition of derivative securities. These standardized codes enable regulatory authorities and investors to quickly identify and categorize the types of insider transactions being disclosed.

The filing was signed on July 17, 2026, by Joshua F. Patterson, identified as attorney-in-fact for Leonard Post, indicating that Post authorized this authorized representative to execute the Form 4 filing on his behalf. This delegation of signature authority to an attorney-in-fact is a routine practice that streamlines the filing process while maintaining the legal responsibility and accuracy requirements imposed on the reporting person. The two-day delay between the transaction date (July 15) and the filing date (July 17) falls within the standard regulatory window for Form 4 filing requirements.

Market Context and Insider Activity Timing

The spread between Post's acquisition price of $0.60 per share and his sale price of $71.17 per share reflects a significant change in the company's valuation or market perception between when the shares were granted and when they were sold. While the filing does not provide information about when the purchased shares were originally granted or when Post first acquired the options being exercised, the price differential is notable enough to warrant investor attention regarding any corporate developments that may have influenced CG Oncology's share price trajectory.

Insider transactions such as these are closely monitored by market participants and regulatory bodies as potential signals of management confidence or concerns about company prospects. However, the pre-planned nature of Post's sale through the Rule 10b5-1 plan means that the decision to sell was made in March 2026, several months before execution, and therefore reflects management sentiment from an earlier period rather than immediate current views.

Director's Ongoing Equity Commitment

Despite liquidating his common stock holdings on July 15, 2026, Leonard Post maintained substantial exposure to CG Oncology through his beneficially owned director stock options. The 105,077 fully vested options represent a meaningful financial interest in the company's future performance, as their value is directly tied to increases in the company's share price above the $0.60 exercise price. This split between liquidating immediately available shares while maintaining deep option holdings suggests a nuanced view of the director's desired investment posture.

The fully vested status of Post's director options means he has complete discretion regarding when and whether to exercise these options. With an expiration date of July 8, 2028, Post has approximately two years to decide whether to exercise any remaining unexercised options at the $0.60 strike price. The combination of a director position, substantial option holdings, and participation in equity compensation arrangements demonstrates Post's ongoing involvement and investment in CG Oncology's long-term direction.

Regulatory Filing Requirements and Transparency

Form 4 filings represent a critical element of the Securities and Exchange Commission's insider trading disclosure regime, requiring officers, directors, and significant shareholders to report changes in their beneficial ownership within specified timeframes. These filings are made public and provide investors with real-time visibility into trading activity by company insiders, helping to identify patterns of accumulation or disposition that may signal management confidence or concern. The comprehensive nature of the Form 4 filing requirement—covering not only direct transactions but also derivative securities and indirect holdings—ensures that investors have access to a complete picture of insider equity interests.

CG Oncology's disclosure of Leonard Post's transactions through the Form 4 mechanism complies with Section 16(a) of the Securities Exchange Act of 1934, which governs insider reporting obligations for public companies. The detailed tables in the filing capture not only the specific securities involved but also the prices, dates, and ownership forms (direct versus indirect) of all transactions and holdings. This level of detail supports investor analysis and regulatory oversight of insider activity.